Literature DB >> 28107546

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Michal Bar-Natan1, Dina Stroopinsky1, Katarina Luptakova1, Maxwell D Coll1, Arie Apel1, Hasan Rajabi2, Athalia R Pyzer1, Kristen Palmer1, Michaela R Reagan3, Myrna R Nahas1, Rebecca Karp Leaf1, Salvia Jain1, Jon Arnason1, Irene M Ghobrial3, Kenneth C Anderson2, Donald Kufe2, Jacalyn Rosenblatt1, David Avigan1.   

Abstract

Multiple myeloma (MM) is a lethal haematological malignancy that arises in the context of a tumour microenvironment that promotes resistance to apoptosis and immune escape. In the present study, we demonstrate that co-culture of MM cells with stromal cells results in increased resistance to cytotoxic and biological agents as manifested by decreased rates of cell death following exposure to alkylating agents and the proteosome inhibitor, bortezomib. To identify the mechanism of increased resistance, we examined the effect of the co-culture of MM cells with stroma cells, on expression of the MUC1 oncogene, known to confer tumour cells with resistance to apoptosis and necrosis. Co-culture of stroma with MM cells resulted in increased MUC1 expression by tumour cells. The effect of stromal cell co-culture on MUC1 expression was not dependent on cell contact and was therefore thought to be due to soluble factors secreted by the stromal cells into the microenvironment. We demonstrated that MUC1 expression was mediated by interleukin-6 and subsequent up-regulation of the JAK-STAT pathway. Interestingly, the effect of stromal cell co-culture on tumour resistance was partially reversed by silencing of MUC1 in MM cells, consistent with the potential role of MUC1 in mediating resistance to cytotoxic-based therapies.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  MUC1; STAT-3; bortezomib; multiple myeloma; stroma cells

Mesh:

Substances:

Year:  2017        PMID: 28107546      PMCID: PMC5800979          DOI: 10.1111/bjh.14493

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  49 in total

1.  MUC1 expression in plasmacytoma.

Authors:  S Paydaş; B Sahin; G Gönlüşen; B Hazar; S Zorludemir
Journal:  Leuk Res       Date:  2001-03       Impact factor: 3.156

2.  MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells.

Authors:  Hasan Rajabi; Rehan Ahmad; Caining Jin; Michio Kosugi; Maroof Alam; Maya Datt Joshi; Donald Kufe
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

3.  Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

Authors:  D Gupta; S P Treon; Y Shima; T Hideshima; K Podar; Y T Tai; B Lin; S Lentzsch; F E Davies; D Chauhan; R L Schlossman; P Richardson; P Ralph; L Wu; F Payvandi; G Muller; D I Stirling; K C Anderson
Journal:  Leukemia       Date:  2001-12       Impact factor: 11.528

Review 4.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

5.  Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.

Authors:  Li Yin; Turner Kufe; David Avigan; Donald Kufe
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

Review 6.  The microenvironment and molecular biology of the multiple myeloma tumor.

Authors:  Miguel Lemaire; Sarah Deleu; Elke De Bruyne; Els Van Valckenborgh; Eline Menu; Karin Vanderkerken
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

7.  IL-6 and IL-8 production by human bone marrow stromal cells.

Authors:  F Rougier; E Cornu; V Praloran; Y Denizot
Journal:  Cytokine       Date:  1998-02       Impact factor: 3.861

8.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

9.  Human DF3/MUC1 carcinoma-associated protein functions as an oncogene.

Authors:  Yongqing Li; Derek Liu; Dongshu Chen; Surender Kharbanda; Donald Kufe
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

10.  Interleukin-6 inhibits apoptosis of malignant plasma cells.

Authors:  A Lichtenstein; Y Tu; C Fady; R Vescio; J Berenson
Journal:  Cell Immunol       Date:  1995-05       Impact factor: 4.868

View more
  11 in total

1.  MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.

Authors:  A R Pyzer; D Stroopinsky; J Rosenblatt; E Anastasiadou; H Rajabi; A Washington; A Tagde; J-H Chu; M Coll; A L Jiao; L T Tsai; D E Tenen; L Cole; K Palmer; A Ephraim; R K Leaf; M Nahas; A Apel; M Bar-Natan; S Jain; M McMasters; L Mendez; J Arnason; B A Raby; F Slack; D Kufe; D Avigan
Journal:  Leukemia       Date:  2017-05-30       Impact factor: 11.528

2.  Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolution.

Authors:  Christina Mark; Natalie S Callander; Kenny Chng; Shigeki Miyamoto; Jay Warrick
Journal:  Integr Biol (Camb)       Date:  2022-06-08       Impact factor: 3.177

Review 3.  Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.

Authors:  Jonas Schwestermann; Andrej Besse; Christoph Driessen; Lenka Besse
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 4.  MUC1 in hematological malignancies.

Authors:  Dina Stroopinsky; Donald Kufe; David Avigan
Journal:  Leuk Lymphoma       Date:  2016-06-27

5.  BAFF is involved in macrophage-induced bortezomib resistance in myeloma.

Authors:  Jing Chen; Donghua He; Qingxiao Chen; Xing Guo; Li Yang; Xuanru Lin; Yi Li; Wenjun Wu; Yang Yang; Jingsong He; Enfan Zhang; Qing Yi; Zhen Cai
Journal:  Cell Death Dis       Date:  2017-11-02       Impact factor: 8.469

Review 6.  Multiple Roles of Glycans in Hematological Malignancies.

Authors:  Xingchen Pang; Hongjiao Li; Feng Guan; Xiang Li
Journal:  Front Oncol       Date:  2018-09-06       Impact factor: 6.244

Review 7.  Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment.

Authors:  Yidi Qu; Bo Dou; Horyue Tan; Yibin Feng; Ning Wang; Di Wang
Journal:  Mol Cancer       Date:  2019-03-30       Impact factor: 27.401

8.  Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.

Authors:  Jahangir Abdi; Nasrin Rastgoo; Yan Chen; Guo An Chen; Hong Chang
Journal:  BMC Cancer       Date:  2019-10-21       Impact factor: 4.430

9.  Reflections on Cancer in the Bone Marrow: Adverse Roles of Adipocytes.

Authors:  Carolyne Falank; Heather Fairfield; Michaela R Reagan
Journal:  Curr Mol Biol Rep       Date:  2017-10-19

10.  USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-κBp65.

Authors:  Lili Zhou; Hua Jiang; Juan Du; Lu Li; Rong Li; Jing Lu; Weijun Fu; Jian Hou
Journal:  Exp Mol Med       Date:  2018-11-20       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.